+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID06730373

Comparing Disitamab Vedotin Plus Sintilimab and S-1 Versus Trastuzumab Plus Chemotherapy Sintilimab for First-Line Treatment of HER2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Led by Qilu Hospital of Shandong University · Updated on 2026-09-15

110

Participants Needed

20

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating treatments for adults with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma that cannot be surgically removed or has spread to other parts of the body. This Phase II, randomized, open-label trial compares a combination of Disitamab Vedotin, Sintilimab, and S-1 against Trastuzumab plus chemotherapy with or without Sintilimab as first-line treatments. The study aims to assess which approach offers better results in controlling this type of stomach cancer. Participants will receive one of two treatment combinations. The experimental group is given Disitamab Vedotin intravenously every 3 weeks, Sintilimab intravenously every 3 weeks, and oral S-1 twice daily for 14 days in a 3-week cycle. The comparison group receives Trastuzumab intravenously with an initial loading dose followed by maintenance doses every 3 weeks, combined with chemotherapy drugs such as Oxaliplatin, Capecitabine, 5-FU, or Cisplatin, with or without Sintilimab. Treatments continue as per protocol to evaluate effectiveness and safety. Throughout the study, participants will undergo regular assessments to measure tumor response, progression-free survival, overall survival, duration of relief, and safety through monitoring adverse events. These evaluations include imaging scans to track measurable lesions based on RECIST 1.1 criteria, laboratory tests, and clinical examinations. The total study duration extends up to approximately two years, including follow-up for safety and outcomes, to gather comprehensive data on these treatment regimens.

CONDITIONS

Brief Title

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Research Team

L

Lian Liu, MD

S

Song Li, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here